Oculis Secures Full Worldwide Rights to Privosegtor, Eliminating Legacy Royalties
OCS sits 23% above its 52-week low of $10.52.
Summary
Oculis acquires full worldwide rights to Privosegtor from Accure Therapeutics for $3.8M cash and up to 2.05M shares, terminating legacy royalties and consolidating control of its lead neuro-ophthalmology asset.
Key Events · M&A and Partnerships · OCS
-
Full Rights Acquired for Privosegtor
Through an asset purchase agreement with Accure Therapeutics, Oculis acquires all worldwide development and commercial rights to Privosegtor (ACT-01) and the preclinical candidate ACT-02. The existing license agreement is terminated, eliminating future milestone payments and royalties.
-
Consideration: $3.8M Cash + 2.05M Shares
Total consideration includes an upfront cash payment of $3.8 million and up to 2,050,000 Oculis ordinary shares, consisting of upfront shares subject to a 2-year lockup and earnout shares vesting upon achievement of development and regulatory milestones.
-
Strategic Timing After OCS-01 Failure
The acquisition follows the May 2026 Phase 3 failure of OCS-01 in diabetic macular edema, making Privosegtor Oculis's most advanced asset. Consolidating ownership now strengthens the company's pipeline focus and economic upside ahead of key catalysts.
-
Registrational Trials Ongoing; IND for MS Relapses in Q4 2026
Privosegtor is currently in the PIONEER registrational program for optic neuritis and NAION. An IND submission for acute MS relapses is planned for Q4 2026, following positive FDA pre-IND feedback.
Analysis · OCS · Life Sciences
Oculis is buying out Accure Therapeutics' remaining rights to Privosegtor, its lead neuroprotective candidate, for $3.8 million cash and up to 2.05 million shares. This terminates the legacy license agreement, removing future milestone payments and royalties — a move that significantly increases Oculis's economic stake in a drug already in registrational trials. The deal comes just months after the Phase 3 failure of OCS-01, making Privosegtor the company's most advanced asset. Securing full control now, ahead of an IND submission for acute MS relapses planned for Q4 2026, strengthens Oculis's negotiating position and long-term value proposition.
At the time of this filing, OCS was trading at $12.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $724.9M. The 52-week trading range was $10.52 to $34.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.